Neoplasia: review time and acceptance speed
ISSN 1476-5586 · ISSN 1522-8002 · Elsevier BV · Biochemistry, Genetics and Molecular Biology
Half of the articles Neoplasia accepted in 2025 were accepted within 79 days of submission (n = 133); the middle half took 43–117 days.
Accepted articles only · dates deposited by the publisher in PubMed · data as of Sep 15, 2026
How long does Neoplasia take to accept a paper?
| Year | Articles (n) | 25th pct | Median | 75th pct | 90th pct | Accepted <14 days | Have a revised date |
|---|---|---|---|---|---|---|---|
| 2025 | 133 | 43 | 79 | 117 | — | 2.3% | 68% |
| 2024 | 129 | 49 | 82 | 138 | — | 3.1% | 72% |
| 2023 | 79 | 69 | 94 | 143 | — | 3.8% | 67% |
| 2022 | 91 | 64 | 85 | 121 | — | 4.4% | 71% |
| 2021 | 100 | 53 | 78 | 100 | — | 2.0% | 83% |
| 2020 | 81 | 45 | 61 | 98 | — | 2.5% | 94% |
- 2026: not shown yet — a year is reported once late-indexed articles have arrived (at least 180 days after it ends).
Distribution in 2025
Show as a table
| Days | Articles | Share |
|---|---|---|
| 0–29 | 12 | 9.0% |
| 30–59 | 38 | 28.6% |
| 60–89 | 25 | 18.8% |
| 90–119 | 27 | 20.3% |
| 120–149 | 10 | 7.5% |
| 150–179 | 9 | 6.8% |
| 180–209 | 5 | 3.8% |
| 210–239 | 5 | 3.8% |
| 240–269 | 0 | 0.0% |
| 270–299 | 0 | 0.0% |
| 300–329 | 1 | 0.8% |
| 330–359 | 0 | 0.0% |
| 360+ | 1 | 0.8% |
From acceptance to online publication
After acceptance, half of the 2025 articles appeared online within 8 days (middle half 7–13 days, n = 133).
From submission to online publication, the median was 86 days (middle half 54–131 days, n = 133).
Read these numbers carefully
- These times describe articles the journal accepted. Rejected manuscripts never appear in public data, so they cannot tell you how long a rejection takes.
- Dates are the ones the publisher deposited with PubMed. Some publishers record the date a revised manuscript arrived as the submission date, which makes review look faster.
- Invited articles and special issues can move faster than regular submissions.
Open access status and publishing fees
Open access (listed in DOAJ). Listed APC: $3,790 (DOAJ).
Institutions reported paying a median of about $3,074 per article (2023–2025, 9 reported payments in OpenAPC; converted from euros at yearly ECB average rates).
Many journals waive or reduce fees for authors from eligible countries or institutions with publishing agreements — check with the journal and your library.
Integrity and indexing signals
Facts from public records, shown without judgement. See the methodology for why each can be worth a closer look.
| Listed in DOAJ | Yes (DOAJ record) |
|---|---|
| Articles indexed for MEDLINE in 2025 | Yes |
| Retractions | 1 retracted article among 532 added to PubMed in 2021–2025 (1.88 per 1,000), per the Retraction Watch Database. |
| Accepted within 14 days of submission | 2.3% of 2025 articles |
| Publication volume | 131 articles added to PubMed in 2025 (-2% vs 2024). |
Topics and scope
- Cancer, Hypoxia, and Metabolism (8% of indexed topics)
- Cancer-related Molecular Pathways (7% of indexed topics)
- Cancer Cells and Metastasis (7% of indexed topics)
- Epigenetics and DNA Methylation (6% of indexed topics)
- Angiogenesis and VEGF in Cancer (5% of indexed topics)
- Prostate Cancer Treatment and Research (4% of indexed topics)
Biochemistry, Genetics and Molecular Biology journalsMedicine journalsMolecular Biology journalsOncology journals
Similar journals — faster or cheaper, side by side
Journals publishing on the most similar topics (OpenAlex), ordered by similarity. Only 2025 figures are compared with the 2025 median of Neoplasia, 79 days.
| Paid APC median | DOAJ | MEDLINE | |||
|---|---|---|---|---|---|
| Cancer and Metastasis Reviews | 122 (2025, n = 69) | ≈$3,790 | — | No | Yes |
| Molecular Cancer Research | 195 (2025, n = 71) | — | — | No | Yes |
| Oncogenesis | 178 (2025, n = 51) | $4,390 | — | Yes | No |
| Cancer Science | 120 (2025, n = 276) | $2,600 | — | Yes | Yes |
| Cancer Cell | 206 (2025, n = 203) | ≈$10,400 | — | No | Yes |
| Biochimica et Biophysica Acta (BBA) - Reviews on Cancer | 131 (2025, n = 262) | ≈$5,070 | — | No | Yes |
| International Journal of Oncology | 98 (2025, n = 86) | — | — | No | Yes |
| Oncogene | 182 (2025, n = 315) | ≈$5,990 | $5,028 (7 payments) | No | Yes |
| Molecular Oncology | 153 (2025, n = 193) | $4,730 | $3,784 (6 payments) | Yes | Yes |
No journals match these filters.
Frequently asked questions
How long does Neoplasia take to accept a paper?
Half of the articles Neoplasia accepted in 2025 were accepted within 79 days of submission (n = 133); the middle half took 43–117 days. Based on dates in PubMed for accepted articles only.
How long after acceptance are Neoplasia articles published online?
Half of the articles accepted in 2025 appeared online within 8 days of acceptance (n = 133).
Does Neoplasia charge an article processing charge (APC)?
Listed APC: $3,790 (DOAJ).
Sources and method
Journal identity: ISSN-L 1476-5586; NLM ID 100886622; OpenAlex record. Speed figures use 133 articles accepted in 2025 with valid dates; excluded records for that year: none.
Spotted a problem with this journal's data, or are you the publisher? Report a correction or email rafiq@gradsummit.com. Verified errors are corrected within five business days.
Get the free Journal Submission Go/No-Go Checklist
The pre-submission checks from Write and Publish a Scientific Paper: journal fit, formatting, cover letter and reviewer suggestions. We’ll email you the download link.
Data sources. Submission, acceptance and publication dates: Courtesy of the U.S. National Library of Medicine (PubMed, entries through Sep 15, 2026). NLM does not endorse Journal Clock, and these figures may not reflect the most current PubMed data. Journal fees and open-access listing: DOAJ (CC0, retrieved Sep 16, 2026). Fees paid by institutions: OpenAPC (Open Database License, retrieved Sep 16, 2026). Retractions: Retraction Watch Database via Crossref (retrieved Sep 16, 2026). Journal identifiers and topics: OpenAlex (CC0). Currency conversion: ECB reference rates (Sep 15, 2026). How these numbers are calculated · For organisations.